Adalimumab (ADA) and Infliximab (IFX) therapy during pregnancy in IBD: a prospective assessment of outcome, safety and cord blood levels

Introduction: Disease activity is a major risk factor for gestational complications in IBD. Data on anti-TNFα therapy are still scare. Cord blood levels have been assessed in newborns with IFX, suggesting discontinuation of treatment prior to the third trimester avoiding neonatal exposure. Few data are published on ADA cord blood levels, guiding adequate cessation prior to birth. Aims & Methods: We aimed to evaluate safety and impact of anti-TNFα therapy on fetal development and pregnancy outcome including the assessment of ADA and IFX cord blood levels. Women with Crohn's disease (CD) or ulcerative colitis (UC)…